Methylation of the SULF2 promoter has been associated with better survival of resected lung adenocarcinoma patients, and also with a marginal improvement in survival of advanced NSCLC patients receiving standard chemotherapy (hazard ratio = 0.63, P = 0.07) [18]. The gene discussed is SULF2; the disease is lung adenocarcinoma.